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The objectives of this special issue on paraoxonases (PONs)
are to bring the latest aspects of paraoxonases (PON 1, 2,
3) research on the genetics, biochemistry, cell biology, and
structural biology of PONs. The issue also addresses the
role of PONs in human diseases (cardiovascular, cancer,
renal failure, and gastrointestinal disorders). Inﬂammatory
and oxidative stress-related diseases, such as diabetes or
rheumatoid arthritis are also favorably aﬀected by PON.
PONs also provide microbial protection by hydrolyzing
bacterial quorum lactone.
The pivotal role of the PON family in a variety of
inﬂammatory diseases, and in preventing the toxicity of
organophosphorus insecticides and nerve agents, has made
PONs an interesting target for both clinicians and scientists
alike. Research into the paraoxonase family of enzymes has
increased dramatically, especially following the initiation of
the paraoxonase conferences. Five international conferences
on paraoxonases were organized between 2004 and 2012,
where the PON scientiﬁc community gathered to discuss
PONs research achievements and future scientiﬁc directions.
These meetings took place in Ann Arbor (MI), Debrecen
(Hungary), Los Angeles (CA), La Pineda (Spain), and
Columbus (OH). According to PubMed, only few PON
paperswerepublishedbefore1980.From1980tillthesedays,
about 3000 papers were published.
The PONs gene cluster contains three adjacent gene
members, and all of the three PON genes share high
sequence, indentify a similar β propeller protein structure,
and hydrolyze esterase/lactonase activities.
PONs play a clear protective role against cardiovascular
diseases.MajorcardioprotectivePONcharacteristicsinclude,
beside their potent antioxidant properties, the following:
for PON 1, favorable eﬀects on macrophage cholesterol
metabolism, for PON 2, attenuation of macrophage triglyc-
eride accumulation, and for PON 3, improvement in bile
acids metabolism.
Human serum HDL-associated paraoxonase (PON1) is
an esterase that possesses cardiovascular protective prop-
erties which result in the following antiatherogenic func-
tions: (1) attenuated oxidative stress in serum, in lipopro-
teins, in macrophages, and in atherosclerotic lesions; (2)
decreased oxidized LDL uptake by macrophages; (3) inhib-
ited macrophage cholesterol biosynthesis rate; (4) stimulated
HDL-mediated cholesterol eﬄux from macrophages.
Major PON1 inactivators (and reversal of their action)
include (1) oxidative stress (and reversal eﬀect by antioxi-
dants such as the pomegranate polyphenolic tannin puni-
calagin); (2) high cholesterol (and reversal eﬀect by statins);
(3)hightriglycerides(andreversaleﬀectbyﬁbrates);(4)high
g l u c o s e( a n dr e v e r s a le ﬀect by insulin).
Macrophage PON2 regulation (as related to atheroge-
nesis) diﬀers from that of serum PON 1 in the following
characteristics: (1) stimulation (not inhibition as shown
for PON1) by oxidative stress and also by anti oxidants
(like PON1); (2) stimulation by high glucose (PON1 is
inhibited) and also by insulin (like PON1); (3) stimulation
by urokinase plasminogen activator (uPA); (4) stimulation
by high triglycerides (PON1 is inhibited); (5) stimulation by
arachidonic acid and also by its product prostaglandin E2
(like PON1); (6) inhibition by high cholesterol and reversal
eﬀect by statins (like PON1).
Figure 1 summarizes our current view on the antiathe-
rosclerotic properties of circulatory HDL-bound PON1 and
those of cellular PON2. Reduction in speciﬁc oxidized lipids
in the blood, in arterial lipoproteins (LDL, HDL), and in
macrophages, by overexpressing humoral PON1 (and also2 Journal of Lipids
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PON antiatherogenicity involves action on cholesterol, oxidative stress, triglycerides, diabetes, and blood
pressure. Atherogenesis involves a yin and a yang downregulation of PONs (including reversible and
Figure 1
cellular PON2), could thus be important target for the
attenuation of atherosclerosis development.
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